611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Medical Disorders
Basic InformationLookupsLatest News
Smog Tied to Raised Risk for Parkinson's, Alzheimer's DiseaseWhat Will Convince Americans to Get a COVID-19 Vaccine?Curbing COVID Brought Unexpected Benefit for Asthma Patients1 in 3 Americans With Arthritis Say Pain, Symptoms PersistCDC Recommends Face Masks in All Public Transportation SettingsIn Medieval Times, Plagues 'Sped Up' With Each New OutbreakWhat You Need to Know About Your Colon Cancer RiskNewer Rheumatoid Arthritis Drug May Help Ease Tough-to-Treat CasesCelebrate Autumn Traditions Without Raising Your COVID RiskNew Drug Could Extend Life for People With ALSHeart Defects Don't Increase Risk of Severe COVID-19Chinese COVID Vaccine Shows Promise in Early TrialAmerica Sees Daily COVID Cases Pass 60,000 Once AgainCOVID Scored Big at 'Superspreader' Hockey GameAHA News: Belly Fat May Signal Early Heart Issues for Mexican AmericansFDA Approves First Ebola Virus TreatmentAmericans Might Need to Pass on Thanksgiving Gatherings: FauciAHA News: Flu and COVID-19 Are Bad Enough, But They Also Can Raise Stroke RiskYour Blood Type May Predict Your Risk For Severe COVID-19Newborns of Moms With COVID-19 Face Little Infection Risk: StudyCOVID Cases Climbing in 36 StatesBedside COVID-19 Test Faster Than Standard PCR TestNIH Launches Trial of Antibody Drugs Against COVID-19Long-Lasting Immunity Seems to Follow Serious COVID CasesAHA News: How Much Do You Know About Thrombosis? Probably Not EnoughCOVID-19 Taking Huge Toll in Excess U.S. DeathsSecond COVID Vaccine Trial Paused for Unexplained IllnessBlacks, Asians More Likely Than Whites to Have Severe COVIDUpper Midwest Sees COVID-19 Surge as Northeast Worries About a Second WaveRemdesivir Speeds Recovery for COVID PatientsAnimal Study Points to Heating Coil Behind Serious Vaping InjuriesAHA News: Strokes and Heart Attacks Increase When Flu-Like Illnesses RiseZika Epidemic Was More Widespread Than Thought: StudyVirtual Care After Surgery May Be More Convenient For PatientsAlways Be Ready for a Trip to the ERPandemic Silver Lining: Steep Drop in Kids' FracturesAntibiotics May Be Best First Treatment for AppendicitisResearchers Identify Bacteria Responsible for Key Crohn's ComplicationDuring and After Surgery, Pot Users Need More Anesthesia, Painkillers: StudyHeart Patients Need to Be Wary of CoronavirusWearing a Mask Doesn't Cause CO2 PoisoningCOVID-19 ICU Patients Have High Risk of Clots, Research ShowsGot Sciatica? Stay Active and Start Early on Physical TherapyDrug Combo Approved for First-Line Treatment of Mesothelioma8 in 10 COVID-19 Patients Suffer Neurological Symptoms, Study FindsAs Virtual Doctor Visits Spike, Concerns About Equity, Missed Diagnoses GrowFor Maximum Safety, Be Sure to Wash Your Homemade Face Mask: StudyDo Minority Kids Face More Danger During Surgeries?Why Getting a Flu Shot is More Important Than Ever This FallCommon Heartburn Meds Tied to Higher Diabetes Risk
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

Companion Drug Might Help Prevent Kidney Complications of Lupus

HealthDay News
by By Amy NortonHealthDay Reporter
Updated: Sep 16th 2020

new article illustration

WEDNESDAY, Sept. 16, 2020 (HealthDay News) -- Adding a newer drug to standard therapy might help control kidney complications caused by the autoimmune disease lupus, a new clinical trial suggests.

The researchers found that adding the drug, called belimumab, improved patients' likelihood of responding to treatment. That meant a reduction in protein in the urine -- a tell-tale sign of kidney inflammation -- and no significant loss in kidney function.

Experts said the results add to evidence that belimumab helps shield the kidneys from the ravages of lupus.

In the most common form of the disease -- called systemic lupus erythematosus (SLE) -- the immune system mistakenly produces antibodies against the body's own tissue. The onslaught can have widespread effects, damaging the skin, joints, heart, lungs and kidneys.

Up to 60% of people with SLE develop kidney inflammation known as nephritis, according to the Lupus Foundation of America.

There are drugs to treat it, and the prognosis has improved in recent years, said Dr. Michael Ward of the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases, in Bethesda, Md.

But, he said, better treatments are still needed. Around 40% of people with more-severe lupus nephritis develop end-stage kidney failure.

Ward wrote an editorial published with the new findings Sept. 17 in the New England Journal of Medicine.

Belimumab is already approved for controlling lupus symptom flares in patients who do not have nephritis. Ward said the new findings suggest that patients already on the drug might get some added benefit for their kidneys.

But he said the question of whether nephritis patients should add belimumab is trickier.

"I'd describe the benefit as modest," Ward said. And it's unclear, he added, which nephritis patients could get that benefit.

The standard treatment for lupus nephritis includes two drugs that suppress the immune system: intravenous cyclophosphamide and mycophenolate mofetil, an oral drug.

Belimumab, first approved in 2011, also suppresses the immune system but in a more specific way. It's a lab-engineered antibody, given by IV or injection, and it quiets overactivity in immune system cells that produce antibodies.

The trials that spurred the drug's approval did not include people with full-blown nephritis. But some patients had "low-grade" kidney disease, said Dr. Richard Furie, lead researcher on the new trial.

And in those patients, there were signs belimumab benefited the kidneys.

That gave the impetus for this trial, said Furie, who is chief of rheumatology at Northwell Health, in Great Neck, N.Y.

His team recruited 448 lupus nephritis patients in 21 countries and randomly assigned them to one of two groups: One had monthly belimumab infusions added to their regular treatment; the other received placebo infusions.

GlaxoSmithKline, which markets the drug as Benlysta, funded the trial.

After two years, the belimumab group was faring better, the researchers found. Overall, 43% were showing a "primary efficacy renal response," compared to 32% of placebo patients.

That means patients had stable kidney function and a drop in protein in their urine, Furie explained.

But, Ward pointed out, the effect was seen only in patients who had the drug added to mycophenolate -- not those on cyclophosphamide. And it's not clear how to read that.

"It might mean belimumab only enhances the effects of mycophenolate," Ward speculated.

Or, he said, it could mean that belimumab only helps patients with less-severe kidney disease: Doctors may have prescribed cyclophosphamide to patients with worse disease.

Belimumab did appear to be safe. It had expected side effects, like respiratory and urinary tract infections. But there was no increase in serious side effects compared to the placebo -- a finding Ward called "reassuring."

A long-term question is whether adding belimumab would help prevent progression to advanced kidney failure. Ideally, both Furie and Ward said, a trial would look at that. But realistically, that's tough to pull off, since the complication can take many years to arise.

Based on these results, Furie said, "one could argue that nephritis patients should have (belimumab) in addition to the standard of care."

In the real world, though, there is also the matter of cost. Like other "biologic" drugs, belimumab is expensive -- totaling about $35,000 per year.

More information

The Lupus Foundation of America has more on treatment options.